Cl-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK)

被引：211

作者：

Allen, LF

Sebolt-Leopold, J

Meyer, MB

机构：

[1] Pfizer Global Res & Dev, Dept Clin Dev, Ann Arbor Labs, Ann Arbor, MI 48105 USA

[2] Pfizer Global Res & Dev, Dept Oncol, Ann Arbor Labs, Ann Arbor, MI 48105 USA

[3] Dept Canc Mol Sci, Ann Arbor, MI USA

来源：

关键词：

D O I：

10.1053/j.seminoncol.2003.08.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：105 / 116

页数：12

共 100 条

[81] Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435
[82] Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
Sebolt-Leopold, JS
Dudley, DT
Herrera, R
Van Becelaere, K
Wiland, A
Gowan, RC
Tecle, H
Barrett, SD
Bridges, A
Przybranowski, S
Leopold, WR
Saltiel, AR
[J]. NATURE MEDICINE, 1999, 5 (07) : 810 - 816
[83] Development of anticancer drugs targeting the MAP kinase pathway
Sebolt-Leopold, JS
[J]. ONCOGENE, 2000, 19 (56) : 6594 - 6599
[84] PROTEIN KINASES .7. THE MAPK SIGNALING CASCADE
SEGER, R
KREBS, EG
[J]. FASEB JOURNAL, 1995, 9 (09) : 726 - 735
[85] SEGER R, 1992, J BIOL CHEM, V267, P14373
[86] Hyperexpression of mitogen-activated protein kinase in human breast cancer
Sivaraman, VS
Wang, HY
Nuovo, GJ
Malbon, CC
[J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (07) : 1478 - 1483
[87] Spencer VA, 2000, J CELL BIOCHEM, P27
[88] Strumberg D, 2002, Int J Clin Pharmacol Ther, V40, P580
[89] Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells
Timms, JF
White, SL
O'Hare, MJ
Waterfield, MD
[J]. ONCOGENE, 2002, 21 (43) : 6573 - 6586
[90] Ras activation in human breast cancer
von Lintig, FC
Dreilinger, AD
Varki, NM
Wallace, AM
Casteel, DE
Boss, GR
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2000, 62 (01) : 51 - 62